AIR Option 2: Research Alliance - Ecosystem for Biophotonic Innovation (EBI) Building Sustainability

AIR 选项 2：研究联盟 - 生物光子创新生态系统 (EBI) 建设可持续发展

• 批准号: 1343479
• 负责人: Dennis Matthews
• 金额: $ 80万
• 依托单位: University of California-Davis
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-10-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1343479&HistoricalAwards=false
• 关键词: AIR; Option; Research; Alliance; Ecosystem

This PFI: AIR Research Alliance project focuses on building a sustainable innovation ecosystem in biophotonics, on educating the next generation of entrepreneurs and on accelerating the translation and transfer of key biomedical technologies developed by an NSF Science and Technology Center (STC), the Center for Biophotonics Science and Technology (CBST). The technologies proposed for commercialization in collaboration with our partners will fill technology gaps in the following areas: 1) super-resolution cellular imaging for biology and medicine, 2) novel non-photobleaching labels for imaging of cell dynamics, 3) monitoring cellular response to cancer drugs, and 4) automated blood pathology for disease detection and monitoring. These technologies have the following market-valued features: 1) outstanding image quality at resolutions that are at least 8 times higher (volume-wise) than the diffraction limit, that provide exemplary performance at lower, and thus more forgiving, illumination intensities when compared to leading optical microscopy technologies; 2) provide the ability to use non-photobleaching SERS (surface enhanced Raman scattering) labels for cellular imaging of cell dynamics, for monitoring unique biomarkers that cannot yet be monitored with other techniques; 3) capability to monitor cellular responses to cancer drugs in almost real-time by using Raman cytometry and in a more efficient manner compared with other experimental strategies; and 4) automated, real-time, point-of-care blood testing systems that provide enormous cost savings when compared to impedance-based, large, skilled labor-intensive and expensive commercially-available blood pathology systems. The Ecosystem for Biophotonics Innovation accomplishes this transfer to the market either by working in collaboration with research partners and transferring technologies to them, or via spinoffs, resulting in creation of new jobs (Entrepreneurial Fellows in academia, scientists collaborators in industry, and scientists in startup companies), commercial products for biology and medicine, with the potential to advance research and help patients while also training entrepreneurial scientists and generating licensing and royalty revenues. The partnerships engaged to transfer the technologies to the market domain include: 1) Applied Precision Inc, a GE Healthcare Company - will commercialize software algorithms for next generation super-resolution microscopes; 2) BD Biosciences - will commercialize novel SERS labels for studying cell dynamics; 3) Keaton Raphael Memorial foundation - will invest financial resources to advance technologies for diagnosis and treatment of pediatric cancers and to launch a startup company to commercialize the most promising technologies; 4) SARTA - will provide links to entrepreneurs in the region and educational opportunities; and 5) Tahoe Institute for Rural Health Research - will commercialize the automatic blood pathology system. The potential economic impact is expected to be realized through: 1) employing highly skilled and productive entrepreneurial fellows, faculty, as well as the scientists at our partnering organizations; 2) employing highly skilled scientists in spinoff companies; 3) licensing of technologies; and 4) through product sales (e.g., next generation super-resolution optical microscopes, labels and assays for cellular imaging, assays for monitoring cellular response to cancer drugs, and automated pathology systems), in the next one-to-five years. All these activities will ultimately contribute to the U.S. competitiveness in the biomedical technology market space through ensuring that cutting-edge technologies are commercialized in the U.S. instead of by scientists and companies from other countries and through providing excellent professional development opportunities to talented entrepreneurial fellows who we expect will have innovative and resourceful careers beyond their tenure with EBI. In the short term, the societal impact includes the movement of advanced technologies closer to commercialization, as well as hands-on training and learning for the next generation of scientists and entrepreneurs regardless of whether entrepreneurial fellows pursue careers in academia or in the private sector. In the long term, the societal impact includes enhancement of scientific discovery enabled by cutting-edge instruments, medical devices, techniques and assays, better understanding of biophysical phenomena, and ultimately improved patient care. EBI will also benefit society by strengthening an infrastructure to promote innovation and to educate would-be entrepreneurs, while also enabling universities to more productively partner with private industry.

PFI：AIR 研究联盟项目的重点是建立生物光子学领域的可持续创新生态系统、教育下一代企业家以及加速 NSF 科学技术中心 (STC) 开发的关键生物医学技术的转化和转让。生物光子科学与技术（CBST）。与我们的合作伙伴合作提出的商业化技术将填补以下领域的技术空白：1）用于生物学和医学的超分辨率细胞成像，2）用于细胞动力学成像的新型非光漂白标签，3）监测细胞对癌症药物，4) 用于疾病检测和监测的自动化血液病理学。这些技术具有以下市场价值的特点：1) 出色的图像质量，分辨率至少比衍射极限高 8 倍（体积），在较低的照明强度下提供示范性的性能，因此相比之下更加宽容领先的光学显微镜技术； 2) 提供使用非光漂白 SERS（表面增强拉曼散射）标记进行细胞动力学细胞成像的能力，用于监测其他技术尚无法监测的独特生物标志物； 3) 能够使用拉曼细胞术几乎实时监测细胞对癌症药物的反应，并且与其他实验策略相比更有效； 4) 自动化、实时、即时护理血液检测系统，与基于阻抗的大型、熟练劳动力密集型且昂贵的市售血液病理学系统相比，可节省大量成本。 生物光子学创新生态系统通过与研究伙伴合作并向他们转让技术或通过分拆来实现向市场的转移，从而创造新的就业机会（学术界的创业研究员、工业界的科学家合作者以及初创公司的科学家）公司），生物和医学商业产品，有潜力推进研究并帮助患者，同时还培训创业科学家并产生许可和特许权使用费收入。致力于将技术转移到市场领域的合作伙伴包括： 1) GE医疗集团旗下的Applied Precision Inc将把下一代超分辨率显微镜的软件算法商业化； 2) BD Biosciences - 将用于研究细胞动力学的新型 SERS 标签商业化； 3）基顿·拉斐尔纪念基金会——将投入财政资源来推进儿科癌症诊断和治疗的技术，并成立一家初创公司，将最有前途的技术商业化； 4) SARTA - 将提供与该地区企业家的联系和教育机会； 5) 塔霍农村健康研究所 - 将自动血液病理学系统商业化。潜在的经济影响预计将通过以下方式实现：1）在我们的合作组织中雇用高技能和高生产力的创业研究员、教师以及科学家； 2）在衍生公司中聘用高技能科学家； 3）技术许可； 4) 在未来一到五年内通过产品销售（例如，下一代超分辨率光学显微镜、细胞成像标签和检测、监测细胞对癌症药物反应的检测以及自动化病理系统）。所有这些活动将最终有助于美国在生物医学技术市场领域的竞争力，确保尖端技术在美国而不是由其他国家的科学家和公司商业化，并为我们所培养的有才华的创业人员提供良好的专业发展机会。预计在 EBI 任期结束后将拥有创新且足智多谋的职业生涯。在短期内，社会影响包括先进技术更接近商业化，以及为下一代科学家和企业家提供实践培训和学习，无论企业家是在学术界还是在私营部门追求职业生涯。从长远来看，社会影响包括通过尖端仪器、医疗设备、技术和分析增强科学发现，更好地理解生物物理现象，并最终改善患者护理。 EBI 还将通过加强基础设施来促进创新和教育潜在企业家，同时使大学能够更有效地与私营企业合作，从而造福社会。